REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (REZILIENT3)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05973773 |
|
Recruitment Status :
Recruiting
First Posted : August 3, 2023
Last Update Posted : May 3, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation | Drug: TAS6417 | Phase 3 |
This study will evaluate the efficacy and safety of zipalertinib in combination with standard chemotherapy with pemetrexed and a platinum agent (either carboplatin or cisplatin) in patients with previously untreated, locally advanced or metastatic nonsquamous NSCLC harboring EGFR ex20ins mutations.
The study will be conducted in two parts:
- Part A: Safety lead-in to determine the recommended dose of zipalertinib in combination with standard chemotherapy pemetrexed and a platinum agent (either carboplatin or cisplatin) to be studied in Part B of the study.
- Part B: Randomized, controlled, open-label, multinational Phase 3 study to assess the efficacy and safety of zipalertinib in combination with standard chemotherapy with pemetrexed and a platinum agent (either carboplatin or cisplatin) compared to standard chemotherapy alone. Patients randomized to the chemotherapy-only treatment arm in Part B may receive treatment with zipalertinib as monotherapy after BICR-assessed progressive disease (PD) is documented (optional "crossover arm").
An independent data monitoring committee (IDMC) will be established to monitor interim safety Data.
A treatment cycle is defined as 21 days for both parts of the study.
Part A: Safety Lead-In The primary objective of Part A is to determine the recommended dose of zipalertinib administered in combination with pemetrexed and a platinum agent (either carboplatin or cisplatin) to be studied in the Phase 3 portion of this study.
Approximately 6-12 patients will receive zipalertinib administered at an initial dose of zipalertinib PO BID (Dose Level 1) in combination with pemetrexed and carboplatin or cisplatin on a 21-day cycle. Patients may continue to receive study treatment until documentation of progressive disease (PD) or until other withdrawal criteria are met, whichever comes first. Patients will be enrolled using a rolling-6 design,35 and the determination of the dose of zipalertinib to be used in Part B of the study will be informed by the incidence of dose-limiting toxicities (DLTs) observed during Cycle 1.
Part B: Phase 3 Enrollment into the Phase 3 portion of the study will begin following completion of Part A.
Approximately 260 patients will be randomized on a 1:1 basis to receive pemetrexed and a platinum agent (either carboplatin or cisplatin) with or without zipalertinib on a 21-day cycle.
Carboplatin or cisplatin will be administered for 4 cycles. Patients may continue to receive zipalertinib (experimental study arm) and pemetrexed (both study arms) until documentation of PD or until other withdrawal criteria are met, whichever comes first.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 272 participants |
| Allocation: | Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations |
| Actual Study Start Date : | June 30, 2023 |
| Estimated Primary Completion Date : | July 27, 2026 |
| Estimated Study Completion Date : | August 24, 2026 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Part A (Safety Lead in)
Part A: Safety Lead-In Approximately 6-12 patients will receive zipalertinib administered at an initial dose of zipalertinib PO BID (Dose Level 1) in combination with pemetrexed and carboplatin or cisplatin on a 21-day cycle. Patients may continue to receive study treatment until documentation of progressive disease (PD) or until other withdrawal criteria are met, whichever comes first.
|
Drug: TAS6417
oral tablets
Other Names:
|
|
Experimental: Part B
Enrollment into the Phase 3 portion of the study will begin following completion of Part A. Approximately 260 patients will be randomized on a 1:1 basis to receive pemetrexed and a platinum agent (either carboplatin or cisplatin) with or without zipalertinib on a 21-day cycle. Carboplatin or cisplatin will be administered for 4 cycles. Patients may continue to receive zipalertinib (experimental study arm) and pemetrexed (both study arms) until documentation of PD or until other withdrawal criteria are met, whichever comes first. |
Drug: TAS6417
oral tablets
Other Names:
|
- Part A and B: The rate and severity of treatment emergent AEs [ Time Frame: approximately 5 years ]
- Part A and Part B: Progression-free survival (PFS) by blinded independent central review (BICR) [ Time Frame: approximately 5 years ]
- Part A: The rate and severity of DLTs according to the NCI-Common Terminology Criteria of Adverse Events (CTCAE) v5.0 during Cycle 1 [ Time Frame: approximately 5 years ]
- Part A and Part B: Objective response rate (ORR) [ Time Frame: approximately 5 years ]
- Part A and Part B: Disease control rate (DCR) [ Time Frame: approximately 5 years ]
- Part A and Part B: Duration of response (DoR) [ Time Frame: approximately 5 years ]
- Part A and Part B: Intracranial (i) Overall Response Rate (iORR) [ Time Frame: approximately 5 years ]
- Part A and Part B: Intracranial duration of complete response (iDCR) [ Time Frame: approximately 5 years ]
- Part A and Part B: Intracranial duration of Response (iDoR) [ Time Frame: approximately 5 years ]
- Part B: Overall survival (OS) [ Time Frame: approximately 5 years ]
- Pharmacokinetic (PK) parameter [ Time Frame: approximately 5 years ]Minimum observed concentration (Cmin)
- European Quality of Life 5 Dimensions, 3 Level Version (EQ-5D-3L) [ Time Frame: approximately 5 years ]The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. This scale is numbered from 0 to 100. The higher the score the better the outcome
- European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [ Time Frame: approximately 5 years ]The EORTC QLQ-C30 is a "core questionnaire" which incorporates a range of physical, emotional and social health developed to assess the quality of life of cancer patients. This scale is numbered from 30 to 130. The higher the score equates to better functioning.
- Non-small Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ ) [ Time Frame: approximately 5 years ]The NSCLC- SAQ was developed to incorporate the patient's perspective into evaluation of clinical benefit in advanced non-small cell lung cancer trials.. Qualitative evidence supports 7 items covering 5 symptom concepts with the total score measuring overall severity of the following NSCLC symptoms: cough, pain, dyspnea, fatigue, and appetite. Lower scores indicate lower symptom severity.
- Pharmacokinetic (PK) parameter [ Time Frame: approximately 5 years ]Minimum Plasma Concentration [Cmin]
- Pharmacokinetic (PK) parameter [ Time Frame: approximately 5 years ]Maximum Plasma Concentration [Cmax]
- Pharmacokinetic (PK) parameter [ Time Frame: approximately 5 years ]Area Under Curve [AUC]
- EGFR mutation status [ Time Frame: approximately 5 years ]local central tests results
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion-
- Provide written informed consent.
- ≥18 years of age (or meets the country's regulatory definition for legal adult age, whichever is greater).
- Pathologically confirmed, locally advanced or metastatic nonsquamous NSCLC
-
Has not received any prior systemic treatment for their locally advanced or metastatic nonsquamous NSCLC. Prior adjuvant/neoadjuvant treatment received >6 months prior to first dose of study treatment is allowed for early-stage
NSCLC. Prior monotherapy with an approved EGFR TKI (ie, gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib) as nonstandard first-line therapy for the treatment of locally advanced or metastatic disease is allowed if all of the following criteria are met:
- Treatment duration did not exceed 8 weeks;
- Lack of disease response was documented (radiographically) by an increase in tumor burden (a copy of the computerized tomography [CT] report showing increase in tumor burden from baseline should be submitted);
- Associated toxicities have resolved to baseline; and
- The EGFR TKI was discontinued at least 2 weeks or 4 half-lives prior to randomization, whichever is longer.
Prior therapy with EGFR TKI agents targeting exon20ins mutations including amivantamab, mobocertinib, sunvozertinib, furmonertinib, and poziotinib is not allowed.
-
Documented EGFR mutation status, as determined by local testing performed at a CLIA certified (US) or accredited (outside of the US) local laboratory, defined as follows:
- Part A: EGFR ex20ins or other uncommon single or compound EGFR mutation
- Part B: EGFR ex20ins mutation
- Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFR mutation status and, where possible, other biomarkers. Patients with insufficient tissue (details provided in laboratory manual) may be eligible following discussion with the sponsor; a fresh biopsy will not be required.
-
Patients with brain metastasis(es) who have previously received definitive local treatment and have stable central nervous system (CNS) disease (defined as being neurologically stable and off corticosteroid for at least 2 weeks prior to enrollment) are eligible. If brain metastases are diagnosed on screening imaging, the patient may be rescreened for eligibility after definitive treatment.
b. Asymptomatic brain metastases ≤2 cm in size can be eligible for inclusion if, in the opinion of the Investigator, immediate definitive treatment is not indicated.
- At least one measurable lesion as determined per RECIST 1.1 for patients enrolling to Part B. Patients enrolling to Part A may be enrolled without measurable disease.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Adequate organ function, as defined by the laboratory value
- Have a life expectancy of at least 3 months as assessed by the investigator.
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to administration of the first dose of study treatment. Female patients are not considered to be of childbearing potential if they are postmenopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).
- Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose and for 6 months after the last dose of study treatment or longer, based on local requirements.
Exclusion -
- Is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study.
-
Prior treatment with any of the following within the specific time frame specified:
- Zipalertinib (TAS6417/CLN-081) at any time.
- Thoracic radiotherapy ≤28 days, palliative radiation of nonthoracic disease ≤14 days, or palliative radiation of a single lesion ≤7 days prior to first dose of study treatment.
- Major surgery (excluding placement of vascular access) ≤28 days prior to first dose of study treatment.
- All prescribed medication, over-the-counter medication, vitamin preparations and other food supplements, or herbal medications that are strong or moderate CYP3A4 inducers or inhibitors within 7 days prior to first dose.
- Have any unresolved toxicity of Grade ≥2 from previous anticancer treatment in the neoadjuvant or adjuvant setting, except for Grade 2 alopecia or skin pigmentation. Patients with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the investigator and Sponsor.
- Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or any evidence of clinically active interstitial lung disease.
-
Impaired cardiac function or clinically significant cardiac disease, including any of the following:
- History of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification .
- Serious cardiac arrhythmias requiring treatment.
- Resting corrected QT interval (QTc) >470 msec calculated using Fridericia's formula (QTcF).
- Unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal (GI) absorption of zipalertinib (such as inflammatory bowel disease, malabsorption syndrome, or prior GI resection).
-
History of another primary malignancy ≤2 years prior to the date of first dose of study treatment unless at least one of the following criteria are met:
- Adequately treated basal or squamous cell carcinoma of the skin
- Cancer of the breast or cervix in situ
- Previously treated malignancy, if all treatment for that malignancy was completed at least 2 years prior to first dose of study treatment, and no current evidence of disease
- Concurrent malignancy determined to be clinically stable and not requiring tumor directed treatment
- Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is unstable or not controlled with treatment.
- History of COVID-19 infection within 4 weeks prior to enrolment and/or have persistent, clinically significant pulmonary symptoms related to prior COVID-19 infection.
- Active bleeding disorders.
- Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in structure or class. To platinum-containing drugs (ie, cisplatin, carboplatin), pemetrexed, or any known excipients of these drugs. b. Contraindications toning drugs (ie, cisplatin, carboplatin) or pemetrexed according to the respective local labels.
- History of leptomeningeal disease and spinal cord compression.
- Is unable or unwilling to take dexamethasone, folic acid, and/or vitamin B12 supplementation during treatment with pemetrexed.
- Is pregnant or lactating or planning to become pregnant
- The patient is, in the investigator's opinion, unable or unwilling to comply with the trial procedures.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05973773
| Contact: Taiho Oncology, INC | 609-250-7336 | clinicaltrialinfo@taihooncology.com |
Show 82 study locations
| Responsible Party: | Taiho Oncology, Inc. |
| ClinicalTrials.gov Identifier: | NCT05973773 |
| Other Study ID Numbers: |
TAS6417-301 2023-503575-21 ( EudraCT Number ) |
| First Posted: | August 3, 2023 Key Record Dates |
| Last Update Posted: | May 3, 2024 |
| Last Verified: | May 2024 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | Yes |
|
Exon 20 insertion mutation NSCLC phase 3 Lung disease |
Carcinoma, Non-Small-Cell Lung CLN-081 TAS6417 EGFR |
|
Carcinoma, Non-Small-Cell Lung Carcinoma, Bronchogenic Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms |
Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |